MINNEAPOLIS, Oct. 26, 2017 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced today the election of Dr. Alpna Seth and Dr. Joe Keegan to the company’s board of directors for a first term, effective today. Seth is Chief Operating Officer of Vir Biotechnology, Inc. and Keegan is an advisor to and director for several life science tools companies.


«We are extremely pleased to have such experienced leaders in the biotech industry join our board,» said Robert Baumgartner, Chairman for Bio-Techne. «Dr. Keegan and Dr. Seth bring strong leadership capabilities as well as commercial and science knowledge to our board. We believe they will add great insight and energy to Bio-Techne.»   

Seth joined Vir in July of this year as its COO. Vir integrates diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases. Prior to joining Vir, Seth held a variety of executive roles at Biogen, including most recently as Senior Vice President and Global head of the Biosimilars business for Biogen with headquarters in Switzerland.   

Keegan has held leadership positions in several life science tools and diagnostics companies, including Molecular Devices, Becton Dickinson and Leica, and most recently as President and CEO of ForteBio, Inc. until its sale to Pall Corporation in 2012. Since 2012, Kegan has been a director and advisor for a number of life science tools companies, including publicly-traded Interpace Diagnostics and several private company boards. 

In addition to the election of Seth and Keegan as new board members, shareholders also voted to re-elect all of the other nominees recommended by the board. With the exception of Dr. Karen Holbrook, who is expected to retire December 31, the terms of all elected directors will all expire at the company’s 2018 annual meeting of shareholders.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD’s in situ hybridization detection products — which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotechnology Division, headquartered in Minneapolis, Minnesota. The Protein Platforms Division manufactures innovative protein analysis tools under the ProteinSimple® brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.    

Contact:  David Clair, Investor Relations
               (646) 277-1266


View original content with multimedia:http://www.prnewswire.com/news-releases/bio-techne-adds-two-new-directors-to-its-board-300543947.html

SOURCE Bio-Techne Corporation